102015-09-8Relevant articles and documents
SAR optimization studies on a novel series of 2-anilinopyrimidines as selective inhibitors against triple-negative breast cancer cell line MDA-MB-468
Jo, Jeyun,Kim, Heegyu,Oh, Ji Youn,Kim, Soyeong,Park, Yeong Hye,Choi, Hyeonjin,Jeong, Jee-Yeong,Jung, Young-Suk,Yun, Hwayoung
, (2019)
Triple-negative breast cancers (TNBCs) account for approximately 15% of breast cancer cases and exhibit an aggressive clinical behavior. In this study, we designed and synthesized two series of 2-anilinopyrimidines based on the structure of our previously